{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:39Z","timestamp":1792839699733,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jhep.2017.03.006","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T19:32:07Z","timestamp":1489865527000},"page":"585-602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients"],"prefix":"10.1016","volume":"67","author":[{"given":"Luca S.","family":"Belli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Duvoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Coilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Colle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fagiuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saye","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges Philippe","family":"Pageaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Strazzabosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.03.006_b0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0010","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/lt.21954","article-title":"Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course","volume":"15","author":"Gallegos-Orozco","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jhep.2006.05.001","article-title":"Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12\u201314, 2006)","volume":"45","author":"Samuel","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0020","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2011.12.031","article-title":"Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy","volume":"56","author":"Berenguer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2017.03.006_b0030","first-page":"153","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"66","author":"Pawlotsky","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0035","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"EASL Clinical Practice Guidelines: Liver transplantation","volume":"64","author":"Burra","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0040","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance. AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. AASLD\/IDSA HCV Guidance Panel","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.006_b0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and Ribavirin prevent recurrence of HCV infection after liver transplantation: an open label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.006_b0050","unstructured":"Afdhal N, Everson G, Calleja JL, et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. Presented at the 49th Annual Meeting of the European Association for the Study of the Liver, London, April 9\u201313, 2014. Abstract."},{"key":"10.1016\/j.jhep.2017.03.006_b0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.006_b0060","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with geotype 1 or 4 hepatitis C infection and advanced liver disease: a multicenter, open label, randomized, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2017.03.006_b0065","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Cohort study of the impact of direct antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0070","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.03.006_b0075","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.006_b0080","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27922","article-title":"Safety and efficacy of simeprevir\/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis","volume":"62","author":"Saxena","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.006_b0085","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/liv.13021","article-title":"Sulkowski MS HCV-HIVco-infected patients: no longer a 'special' population?","volume":"36","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.006_b0090","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MOT.0000000000000199","article-title":"Hepatitis C virus-HIV-coinfected patients and liver transplantation","volume":"20","author":"Kardashian","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.jhep.2017.03.006_b0095","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.27723","article-title":"Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis","volume":"61","author":"Jang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.006_b0100","unstructured":"Coilly A, Pageaux GP, Houssel-Debry P, Duvoux C, Radenne S, de Ledinghen V at al. Improving liver function and delisting of patients awaiting liver transplantation for cirrhosis: do we ask too much to DAAs? Presented at 66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13\u201317 2015."},{"key":"10.1016\/j.jhep.2017.03.006_b0105","doi-asserted-by":"crossref","unstructured":"Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L et al. Interferon free antiviral therapy in cirrhotic patients infected with hepatitis c on the waiting list for liver transplantation. Efficacy and impact on delisting and liver function. Abstracts of The International Liver Congress (TM) 2016\u201351th Annual meeting of the European Association for the Study of the Liver \u2028.","DOI":"10.1016\/S0168-8278(16)00969-7"},{"key":"10.1016\/j.jhep.2017.03.006_b0110","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0115","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0120","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected early tumor recurrence in patients with hepatitis C virus- related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0125","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2016.04.033","article-title":"Direct antiviral agents and risk for HCC early recurrence: much ado about nothing","volume":"65","author":"Camma","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0130","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0135","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/liv.13322","article-title":"Prevention of hepatitis C recurrence by bridging sofosbuvir\/ribavirin from pre- to post-liver transplant: a real-life strategy","volume":"37","author":"Donato","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.03.006_b0140","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.jhep.2015.08.010","article-title":"R Esteban. Management of direct-acting antiviral agent failures","volume":"63","author":"Buti","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0145","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.006_b0150","first-page":"183","article-title":"Metabolic and cardiovascular complications in the liver transplant recipient","volume":"28","author":"De Luca","year":"2015","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.006_b0155","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jhep.2010.12.001","article-title":"Immunosuppression in liver transplant recipients with renal impairment","volume":"54","author":"Duvoux","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0160","unstructured":"http:\/\/www.hep-druginteractions.org."},{"key":"10.1016\/j.jhep.2017.03.006_b0165","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2017.03.006_b0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jhep.2010.11.012","article-title":"Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients","volume":"55","author":"Selzner","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.03.006_b0180","first-page":"219A","article-title":"Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: realworld experience in a diverse, longitudinal observational cohort","volume":"60","author":"Jensen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.006_b0185","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.03.006_b0190","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.03.006_b0195","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/lt.24126","article-title":"Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients","volume":"21","author":"Gutierrez","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0200","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/TP.0000000000001126","article-title":"Sofosbuvir-based antiviral therapy is highly effective in recurrent hepatitis C in liver transplant recipients: Canadian multicenter \u201creal-life\u201d experience","volume":"100","author":"Faisal","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2017.03.006_b0205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/lt.24366","article-title":"Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network","volume":"22","author":"Brown","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0210","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.27770","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant","volume":"61","author":"Pungpapong","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.006_b0215","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.006_b0220","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12524","article-title":"Efficacy and safety of sofosbuvir\/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation","volume":"18","author":"Ciesek","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhep.2017.03.006_b0225","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.cgh.2015.05.030","article-title":"Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation","volume":"13","author":"Leroy","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.jhep.2017.03.006_b0230","doi-asserted-by":"crossref","DOI":"10.1002\/lt.24416","article-title":"Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection","author":"Fontana","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0235","doi-asserted-by":"crossref","unstructured":"Colombo M, Aghemo A, Liu L, Hyland R, Yun C, Brainard D, et al. Ledipasvir\/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection Abstracts of The International Liver Congress (TM) 2016\u201351th Annual meeting of the European Association for the Study of the Liver.","DOI":"10.1016\/S0168-8278(16)00116-1"},{"key":"10.1016\/j.jhep.2017.03.006_b0240","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/lt.21644","article-title":"Virology and pathogenesis of hepatitis C virus recurrence","volume":"14","author":"Ram\u00edrez","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0245","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0041-1345(96)00248-5","article-title":"Prophylaxis against HCV recurrence after liver transplantation: effect of interferon and ribavirin combination","volume":"29","author":"Mazzaferro","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2017.03.006_b0250","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bpg.2012.09.010","article-title":"Liver transplantation in the setting of chronic HCV","volume":"26","author":"Terrault","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.006_b0255","first-page":"304","article-title":"Recurrence of hepatitis C after liver transplantation","volume":"26","author":"Vinaixa","year":"2013","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.jhep.2017.03.006_b0260","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1432-2277.2008.00804.x","article-title":"New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies","author":"Chen","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2017.03.006_b0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1432-2277.2002.tb00090.x","article-title":"Hepatitis C virus (HCV)-related cryoglobulinemia after liver transplantation for HCV cirrhosis","volume":"1","author":"Duvoux","year":"2002","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2017.03.006_b0270","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/hep.510300314","article-title":"Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation","volume":"30","author":"H\u00e9zode","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.006_b0275","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00007890-200210270-00008","article-title":"Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients","volume":"74","author":"Duvoux","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2017.03.006_b0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/lt.23566","article-title":"Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation","volume":"19","author":"Lucey","year":"2013","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lt.23756","article-title":"Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease","volume":"20","author":"Bl\u00e9","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0290","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.03.006_b0295","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1053\/jlts.2000.18689","article-title":"Retransplantation for hepatitis C: implications of different policies","volume":"6","author":"Rosen","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0300","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1002\/lt.20259","article-title":"Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility","volume":"10","author":"Burton","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0305","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1537-2995.1997.37597293892.x","article-title":"Six years of experience in virus screening of organ donors in France","volume":"37","author":"Lefrere","year":"1997","journal-title":"Transfusion"},{"key":"10.1016\/j.jhep.2017.03.006_b0310","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1097\/01.ASN.0000034944.90425.75","article-title":"Donor hepatitis C seropositivity: Clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation","volume":"13","author":"Bucci","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2017.03.006_b0315","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1034\/j.1600-6143.2003.00189.x","article-title":"Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis","volume":"3","author":"Saab","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2017.03.006_b0320","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1432-2277.2010.01092.x","article-title":"Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis","volume":"23","author":"Northup","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2017.03.006_b0325","first-page":"44","article-title":"Donor hepatitis C sero-status does not impact survival in liver transplantation","volume":"22","author":"Montenovo","year":"2015","journal-title":"Ann Transplant"},{"key":"10.1016\/j.jhep.2017.03.006_b0330","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2017.03.006_b0335","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/lt.20849","article-title":"Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts","volume":"12","author":"Khapra","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2017.03.006_b0340","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting hepatitis C-positive kidneys","volume":"373","author":"Reese","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781730140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781730140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T16:29:28Z","timestamp":1714580968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882781730140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S016882781730140X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.03.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}